Vaccine Design

1. Front Matter

   Pages i-ix

   PDF

2. The Role of Cytokines in the Action of Immunological Adjuvants

   • Anthony C. Allison

   Pages 1-9

3. The Role of Tumour Necrosis Factor in Lymphoid Tissue Formation and Function

   • Manolis Pasparakis, Eleni Douni, Lena Alexopoulou, George Kollias

   Pages 11-17

4. Dendritic Cells and Cytokines

   • Jonathan M. Austyn

   Pages 19-23

5. Control of HIV Entry and Transcription, as a Possible Mechanism of the Antiviral Effects of T Lymphocytes in HIV Infection

   • J.-L. Virelizier, A. Amara, E. Oberlin, D. Rousset, M. Rodriguez, M. Kroll

   Pages 25-31

6. Development of an Influenza-Iscom™ Vaccine

   • John Cox, Alan Coulter, Rod Macfarlan, Lorraine Beezum, John Bates, Tuen-Yee Wong et al.

   Pages 33-49

7. Development of Parainfluenza Virus and Respiratory Syncytial Virus Subunit Vaccines

   • M. Ewasyshyn, G. Cates, G. Jackson, A. Symington, N. Scollard, R. P. Du et al.

   Pages 51-58

8. Mucosal Vaccines: Perspectives on the Development of Anti-H.pylori Vaccines

   • Paolo Ghiara

   Pages 59-66

9. A Single Treatment with Adjuvant Stimulates Th1-Like Cytokines and Downregulates Th2-Mediated Primary and Secondary Allergic Responses

   • Dorothy E. Scott, Basil Golding

   Pages 67-79

10. Induction of IL-12 Secretion and Enhanced Surface Expression of B7.1/B7.2 and ICAM-1 in Human Monocytes Activated by the Vaccine Carrier Brucella Abortus: Correlation with in Vivo Generation of Cellular Immune Responses

    • H. Golding, M. B. Zaitseva, C. K. Lapham, B. Golding

    Pages 81-97

11. The Potential Use of Different Vaccination Protocols to Tailor Cytokine Profiles

    • Emmanuel Comoy, André Capron, Georges Thyphronitis

    Pages 99-109

12. Modulation of Cytokine Responses by Iscoms and Iscom-Matrix

    • Maria Villacres-Eriksson, Shahriar Behboudi, Karin Lövgren-Bengtsson, Bror Morein

    Pages 111-118

13. Vaccines and Vaccine Delivery Systems: Experience with HSV, Influenza and Mucosal Routes of Immunisation

    • R. Jennings, D. Ní Challanáin, H. O. Ghazi, C. S. McLean

    Pages 119-127

14. Active Immunotherapy for Solid Tumours

    • A. Maraveyas, A. G. Dalgleish

    Pages 129-146

15. Iscoms as Mucosal Vaccine Vectors

    • Allan McI.Mowat, Kevin J. Maloy, Rosemary E. Smith, Anne M. Donachie

    Pages 147-153

16. Adjuvant Directed Immune Specificity at the Epitope Level: Implications for Vaccine Development a Model Study Using Semliki Forest Virus Infection of Mice

    • H. Snippe, I. M. Fernández, C. A. Kraaijeveld

    Pages 155-166

17. Interleukin 1 and Its Synthetic Peptide 163–171 as Vaccine Adjuvants

    • Aldo Tagliabue, Diana Boraschi

    Pages 167-173

18. The Immunological Co-Adjuvant Action of Liposomal Interleukin-15

    • Mayda Gursel, Gregory Gregoriadis

    Pages 175-180

19. Protection Against Tuberculosis by Plasmid DNA

    • R. E. Tascon, M. J. Colston, E. Stavropoulos, S. Ragno, D. Gregory, D. B. Lowrie

    Pages 181-185

20. From Scientific Discovery to Clinical Trial: Overcoming the Regulatory Hurdles — A Guide for Academic Researchers

    • Jillian K. Bennet

    Pages 187-196

• HIV
• cell biology
• cytokine
• infection
• lipide
• lymphocytes
• necrosis
• protein
• proteins
• research
• vaccine
• virus

`This book should be very valuable to anyone interested in the basic design of vaccine strategies or the preclinical evaluation of novel vaccines and adjuvants.'
Doody's Journal
`I have little doubt that this book will become a standard reference for future development of vaccine formulations.'
European Journal of Pharmaceutics and Biopharmaceutics Vaccine Design.

• School of Pharmacy, University of London, London, England

  Gregory Gregoriadis, Brenda McCormack

• Dawa Corporation, Belmont, USA

  Anthony C. Allison

Policies and ethics